Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 24

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 24
---
20 |     |      |               23 |     |      |    45 |     |      |    49 |
| Other           |     |     |                    |      |  23 |     |      |               18 |     |      |    47 |     |      |    33 |
| Total royalties |     |     |                    | $    | 789 |     | $    |              659 |     | $    | 1,378 |     | $    | 1,111 |

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 16/44                  
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
J&J’s net sales of DARZALEX were $6,776 million in the first six months of 2025 compared to $5,570 million in the first six months of 2024. The increase of $1,206 million, or 22%, was driven by market share gains in all regions. Royalty revenue on net sales of DARZALEX was $1,088 million in the first six months of 2025 compared to $885 million in the first six months of 2024, an increase of $203 million. The percentage increase in royalties of 23% is consistent with the percentage increase in the underlying net sales.

Novartis’ net sales of Kesimpta were $1,976 million in the first six months of 2025 compared to $1,436 million in the first six months of 2024. The increase of $540 million, or 38%, was primarily driven by increased demand and strong access. Royalty revenue on net sales of Kesimpta was $198 million in the first six months of 2025 compared to $144 million in the first six months of 2024, an increase of $54 million, or 38%.

Amgen’s net sales of TEPEZZA were $886 million in the first six months of 2025 compared to $903 million in the first six months of 2024. Royalty revenue on net sales of TEPEZZA was $45 million in the first six months of 2025 compared to $49 million in the first